drugset / Trial / NCT05826275
Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.
Timeline
- Start
- 2023-06-20
- Primary completion
- 2025-05-28
- Completion
- 2025-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGN-S11 | Small molecule | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |